Docket 4696-1

1 pas Copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [6]:
C12N 15/31, C07K 14/315, A61K 39/09, C12N 1/21 — A2

(11) International Publication Number: **WO 99/42588**

(43) International Publication Date: 26 August 1999 (26.08.99)

(21) International Application Number: PCT/CA99/00114

(22) International Filing Date: 17 February 1999 (17.02.99)

(30) Priority Data:
60/075,425 — 20 February 1998 (20.02.98) — US

(71) Applicant *(for all designated States except US)*: BIOCHEM VACCINS INC. [CA/CA]; 2323 boulevard du Parc Technologique, Sainte-Foy, Québec G1P 4R8 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BRODEUR, Bernard, R. [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T 1N6 (CA). RIOUX, Clément [CA/CA]; 1012 Jean-Charles Cantin, Ville de Cap Rouge, Québec G1Y 2X1 (CA). BOYER, Martine [CA/CA]; Apt. 204, 25 des Mouettes, Beauport, Québec G1E 7G1 (CA). CHARLEBOIS, Isabelle [CA/CA]; 410 Mirabel, St-Nicolas, Québec G7A 2L5 (CA). HAMEL, Josée [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T 1N6 (CA). MARTIN, Denis [CA/CA]; 4728-G rue Gaboury, St-Augustin-de-Desmaures, Québec G3A 1E9 (CA).

(74) Agents: CÔTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: GROUP B STREPTOCOCCUS ANTIGENS

(57) Abstract

Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.